Paper - WANFANG MED ONLINE

You Position: Home > Paper

气道药物吸入技术的研究进展

( views:250, downloads:789 )

Author:: No author available

Journal Title:: Chinese Journal of Tuberculosis and Respiratory Diseases

Issue:: 12

DOI:: 10.3760/cma.j.issn.1001-0939.2017.12.016

Key Word:: No keyword available

Abstract：药物气道吸入与其他给药方式相比,具有呼吸道局部药物浓度高、起效快、疗效确切以及全身不良反应少等优势.近年来可用于气道吸入的药物种类越来越多,除了常用的支气管舒张剂、黏液溶解剂和糖皮质激素外,还包括抗生素、疫苗和抗高血压药物等[1]. 因此,气道药物吸入技术不断的创新和优化,对确保更高的药物输送和吸入效率,从而提高患者疗效具有重要的作用. 吸入装置主要分为小容量雾化器、加压定量吸入器( pressure meter dose inhaler , pMDI )和干粉吸入器(dry power inhaler,DPI)三大类[2]. 近来出现的新的气道药物吸入技术主要从气溶胶的发生机制、输送方式、设备材质、助推剂、按需雾化及辅助装置等方面进行创新和优化. 本文对近年来气道药物吸入技术的研究进展综述如下.

Reference

[1]龚志晶,关继涛,任雪珠,等.氢气对环卫工人雾霾暴露肺保护性作用的研究[J].2016,(12).
[2]Myers DJ,Cassella JV,Munzar P,etc.Ultra-fast absorption of amorphous pure drug aerosols via deep lung inhalation.[J].2006,95(11).
[3]Lori, Weisfeld,Youyi, Shu,Tushar P, Shah.Bioequivalence of budesonide plus formoterol (BF) Spiromax? and BF Turbohaler? (with and without charcoal block) in healthy volunteers.[J].2015,53(7).
[4]Shen X,Hindle M,Byron PR.Effect of energy on propylene glycol aerosols using the capillary aerosol generator.[J].2004,275(1).
[5]Arzu, Ari,Hasan, Areabi,James B, Fink.Evaluation of aerosol generator devices at 3 locations in humidified and non-humidified circuits during adult mechanical ventilation.[J].2010,55(7).
[6]M L, Goode,J B, Fink,R, Dhand,etc.Improvement in aerosol delivery with helium-oxygen mixtures during mechanical ventilation.[J].2001,163.
[7]Ronald, Dahl,Peter M A, Calverley,Antonio, Anzueto,etc.Safety and efficacy of tiotropium in patients switching from HandiHaler to Respimat in the TIOSPIR trial.[J].2015,5.
[8]Li,H.,Chen,Y.,Zhang,Z.,etc.Handling of diskus dry powder inhaler in Chinese chronic obstructive pulmonary disease patients[J].2014,27(3).
[9]Anushi Rajapaksa,Aisha Qi,Leslie Y. Yeo.Enabling practical surface acoustic wave nebulizer drug delivery via amplitude modulation[J].2014,14(11).
[10]Michotte, Jean-Bernard,Jossen, Emilie,Roeseler, Jean,etc.In Vitro Comparison of Five Nebulizers During Noninvasive Ventilation: Analysis of Inhaled and Lost Doses[J].2014,27(6).
[11]Ricardo F. Oliveira,Jose C.F. Teixeira,Luis F. Silva,etc.Development of new spacer device geometry: a CFD study (Part I)[J].2012,15(7).
[12]Guifang, Zhang,Anand, David,Timothy Scott, Wiedmann.Performance of the vibrating membrane aerosol generation device: Aeroneb Micropump Nebulizer.[J].2007,20(4).
[13]Lewis, D. A.,Ganderton, D.,Meakin, B. J.,etc.Modulite: A Simple Solution to a Difficult Problem.[J].2005,72.
[14]Winfried, M?ller,Irene, Heimbeck,Thomas P J, Hofer,etc.Differential inflammatory response to inhaled lipopolysaccharide targeted either to the airways or the alveoli in man.[J].2012,7(4).
[15].Air-jet and vibrating-mesh nebulization of niosomes generated using a particulate-based proniosome technology[J].2013,444(1).
[16]Francesca, Buttini,Gaetano, Brambilla,Diego, Copelli,etc.Effect of Flow Rate on In Vitro Aerodynamic Performance of NEXThaler(?) in Comparison with Diskus(?) and Turbohaler(?) Dry Powder Inhalers.[J].2016.
[17]Gogate, P.R.,Pandit, A.B.,Ramisetty, K.A..Investigations into ultrasound induced atomization[J].2013,20(1).
[18]Kitty Leung,Emily Louca,Allan L. Coates.Comparison of Breath-Enhanced to Breath-Actuated Nebulizers for Rate, Consistency, and Efficiency[J].2004,126(5).
[19]Daniel Mufson,Alejandro Zaffaroni,Ron Hale,etc.Fast Onset Medications through Thermally Generated Aerosols[J].2004,309(2).
[20]Muller BW,Rasenack N,Steckel H.In-situ-micronization of disodium cromoglycate for pulmonary delivery.[J].2003,55(2).
[21]Lakhal, Karim,Lopes, Carlos,Donzeau, Alexis,etc.Aerosol therapy in intensive and intermediate care units: prospective observation of 2808 critically ill patients[J].2016,42(2).
[22]Petrov,A.,Cook,R.O.,Hoffman,R.M.,etc.Systemic delivery of atropine sulfate by the microdose dry-powder inhaler[J].2013,26(1).
[23]Azouz,W.,Campbell,J.,Stephenson,J.,etc.Improved metered dose inhaler technique when a coordination cap is used[J].2014,27(3).
[24]Moller W,Felten K,Sommerer K,etc.Deposition, retention, and translocation of ultrafine particles from the central airways and lung periphery.[J].2008,177(4).
[25]Needham MJ,Ratner P,Harrison LI,etc.Comparative pulmonary function and pharmacokinetics of fluticasone propionate and salmeterol xinafoate delivered by two dry powder inhalers to patients with asthma.[J].2011,24(5).
[26]Voshaar,T.,Spinola,M.,Linnane,P.,etc.Comparing usability of NEXThaler? with other inhaled corticosteroid/long-acting β2-agonist fixed combination dry powder inhalers in asthma patients[J].2014,27(5).
[27]Yvonne K, Lentz,Thomas J, Anchordoquy,Corinne S, Lengsfeld.Rationale for the selection of an aerosol delivery system for gene delivery.[J].2006,19(3).
[28]Desmond Heng,Sie Huey Lee,Wai Kiong Ng,etc.Novel alternatives to reduce powder retention in the dry powder inhaler during aerosolization.[J].2013,452(1/2).
[29]Kenneth C, Kesser,David E, Geller.New aerosol delivery devices for cystic fibrosis.[J].2009,54(6).
[30]Friebel C,Steckel H.Single-use disposable dry powder inhalers for pulmonary drug delivery.[J].2010,7(12).
[31]Bruce K, Rubin.Pediatric aerosol therapy: new devices and new drugs.[J].2011,56(9).
[32]Gross G,Cohen RM,Guy H.Efficacy response of inhaled HFA-albuterol delivered via the breath-actuated Autohaler inhalation device is comparable to dose in patients with asthma.[J].2003,40(5).
[33]Ari, Arzu,Fink, James B..Differential Medical Aerosol Device and Interface Selection in Patients during Spontaneous, Conventional Mechanical and Noninvasive Ventilation[J].2016,29(2).
[34]Solomita,M.,Lau,S.,Bauer,K.,etc.Delivery and safety of inhaled interferon-γ in idiopathic pulmonary fibrosis[J].2012,25(2).
[35].Six-month in vitro validation of a metered-dose inhaler electronic monitoring device: Implications for asthma clinical trial use[J].2012,130(6).
[36]Longest,P.W.,Mandana,A.,Golshahi,L.,etc.Improving aerosol drug delivery during invasive mechanical ventilation with redesigned components[J].2014,59(5).
[37]Hindle,M.,Son,Y.-J.,Longest,P.W.,etc.Evaluation and modification of commercial dry powder inhalers for the aerosolization of a submicrometer excipient enhanced growth (EEG) formulation[J].2013,49(3).
[38]LaForce C,Staudinger H,Weinstein C,etc.Dose counter performance of mometasone furoate/formoterol inhalers in subjects with asthma or COPD.[J].2011,105(7).
[39]Stephen P, Newman.Principles of metered-dose inhaler design.[J].2005,50(9).